Mycophenolate Mofetil Initiation in Renal Transplant Patients at Different Times Posttransplantation: The TranCept Switch Study

被引:9
|
作者
Meier-Kriesche, Herwig-Ulf [1 ]
Merville, Pierre [2 ]
Tedesco-Silva, Helio [3 ]
Heemann, Uwe [4 ]
Kes, Petar [5 ]
Haller, Hermann [6 ]
Rostaing, Lionel [7 ]
Gafner, Nesrin [8 ]
Bernasconi, Corrado [9 ]
机构
[1] Univ Florida, Coll Med, Div Nephrol, Gainesville, FL 32610 USA
[2] Hop Pellegrin, Serv Nephrol Transplantat Dialyse, F-33076 Bordeaux, France
[3] Univ Fed Sao Paulo, Hosp Rim & Hipertensao, Sao Paulo, Brazil
[4] Tech Univ Munich, Klinikum Rechts Isar, Chirurg Klin, D-8000 Munich, Germany
[5] Univ Hosp Ctr Zagreb, Dept Internal Med, Zagreb, Croatia
[6] Hannover Med Sch, Nephrol Abt, D-30623 Hannover, Germany
[7] CHU Rangueil, Dept Nephrol Dialysis & Organ Transplantat, F-31054 Toulouse, France
[8] Nesrin Gafner Consulting, Biel, Switzerland
[9] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
关键词
Mycophenolate mofetil; Calcineurin inhibitor withdrawal; Glomerular filtration rate; Nephrotoxicity; CHRONIC ALLOGRAFT NEPHROPATHY; CYCLOSPORINE; DYSFUNCTION; REDUCTION; RISK;
D O I
10.1097/TP.0b013e3182130966
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Despite evidence of favorable long-term effects of mycophenolate mofetil (MMF) in renal transplantation, its introduction at different times posttransplant has not been studied in large cohorts. Methods. Single-organ renal allograft recipients (n=2217) who had MMF introduced 6 months to more than 20 years posttransplantation for various reasons were included in TranCept Switch, a multicenter, noninterventional, observational 4-year study. Changes in renal function before and after the introduction of MMF were analyzed. Results. MMF was introduced because of renal function decline in 43% of patients and poor tolerability with previous treatment in 23% of patients. The change in slope of the calculated glomerular filtration rate (modification of diet in renal diseases formula) regression line before and after MMF initiation was +2.01 mL/min per year (P<0.001) on average. The greatest benefit was noted in patients who received MMF because of renal function decline and in whom calcineurin inhibitor treatment was subsequently reduced or withdrawn (+3.09 mL/min per year). Time from transplantation to MMF introduction influenced the glomerular filtration rate at MMF initiation (slow progressive deterioration) but not the direction of the slope change, which was positive even for late introduction. Conclusion. MMF introduction may be associated with improvement or stabilization of renal function even several years after transplantation.
引用
收藏
页码:984 / 990
页数:7
相关论文
共 50 条
  • [1] Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the TranCept STAY study
    Heemann, Uwe
    Kliem, Volker
    Budde, Klemens
    Hamza, Amir
    Juergensen, Jan Steffen
    Juarez, Federico
    Arns, Wolfgang
    Rath, Thomas
    Haller, Hermann
    [J]. CLINICAL TRANSPLANTATION, 2012, 26 (06) : 919 - 926
  • [2] FULL DOSE MYCOPHENOLATE MOFETIL (CELLCEPT®) WITH LOW DOSE TACROLIMUS OPTIMIZES RENAL FUNCTION IN LONG TERM RENAL TRANSPLANT PATIENTS; RESULTS OF THE TRANCEPT STAY STUDY
    Heemann, U.
    Kliem, V.
    Hamza, A.
    Budde, K.
    Juarez de la Cruz, F. J.
    Ams, W.
    Juergensen, J. S.
    Haller, H.
    [J]. TRANSPLANT INTERNATIONAL, 2010, 23 : 47 - 47
  • [3] Withdrawal of mycophenolate mofetil in stable renal transplant patients
    Kaplan, B
    Meier-Kriesche, HU
    Friedman, G
    Mulgaonkar, S
    Vaghela, M
    Duva, D
    Nittoly, M
    Jacobs, M
    [J]. TRANSPLANTATION, 1999, 67 (07) : S116 - S116
  • [4] The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients
    Abderahmene, Amani
    Ellouz, Amel
    Amor, Dorra
    Ajmi, Marwa
    Khalij, Yassine
    Hamdouni, Haithem
    Sahtout, Wissal
    Azzabi, Awatef
    Omezzine, Asma
    Achour, Abdellatif
    Bouslama, Ali
    [J]. PERSONALIZED MEDICINE, 2022, 19 (05) : 383 - 393
  • [5] Mycophenolate mofetil intolerance in paediatric renal transplant patients
    Dharmawardane, Harshini
    Shenoy, Mohan
    Webb, Nicholas J. A.
    [J]. PEDIATRIC NEPHROLOGY, 2012, 27 (09) : 1829 - 1829
  • [6] Incidence of Infections after Two Different Doses of Mycophenolate Mofetil in Renal Transplant Patients
    Hoelzen, J. P.
    Wigger, B.
    Vogel, T.
    Kebschull, L.
    Palmes, D.
    Suwelack, B.
    Wolters, H. H.
    [J]. TRANSPLANTATION, 2012, 94 (10) : 977 - 977
  • [7] Benefit of mycophenolate mofetil in immunized renal transplant patients.
    Kliem, V
    vonWoellwarth, J
    Behrend, M
    Schlitt, HJ
    Nashan, B
    Koch, KM
    Pichlmayr, R
    Brunkhorst, R
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3211 - A3211
  • [8] Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients
    Aigrain, EJ
    Shaghaghi, EK
    Baudouin, V
    Popon, M
    Loirat, C
    [J]. TRANSPLANTATION PROCEEDINGS, 2000, 32 (02) : 388 - 390
  • [9] Steroid Toxicity and Mycophenolate Mofetil Therapy in Renal Transplant Patients
    Kocak, Huseyin
    Dinckan, Ayhan
    Demirbas, Alper
    [J]. TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, 2008, 17 : 25 - 28
  • [10] GASTROINTESTINAL TRANSIT IN RENAL TRANSPLANT PATIENTS TREATED WITH MYCOPHENOLATE MOFETIL
    Cora, Luciana
    Borges Teixeira, Maria Carmo
    Barreto, Thayrone Miranda
    Oliveira, Thainara Torres
    Oliveira, Ricardo Brandt
    Arruda Miranda, Jose Ricardo
    [J]. TRANSPLANT INTERNATIONAL, 2013, 26 : 287 - 288